ASCO 2025: Dr. Liu Discusses the Most Anticipated Thoracic Oncology Data To Be Presented

Stephen V. Liu, MD, of the Georgetown University School of Medicine and Georgetown’s Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the most anticipated thoracic oncology data that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.

“At ASCO 2025, we do expect to see results from some practice-changing studies and a lot of practice-informing studies,” Dr. Liu said. “It’s a big year for lung cancer at ASCO 2025.”

He explained that some of the most impactful research on the agenda at this year’s meeting will be the IMFORTE trial data to be presented by Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 de Octubre, and the primary analysis of the phase 3 DeLLphi-304 trial to be presented by Charles M. Rudin, MD, PhD, of the Memorial Sloan Kettering Cancer Center.

“Two of the biggest stories are going to be in small cell lung cancer,” Dr. Liu said.

In non–small cell lung cancer (NSCLC), there are also multiple key developments and presentations to watch.

“A big story will be in early-stage resectable lung cancer,” Dr. Liu. “We are finally going to see the overall survival data from CheckMate 816.”

The CheckMate 816 data on overall survival with neoadjuvant nivolumab plus chemotherapy in patients with resectable NSCLC will be presented by Patrick M. Forde, MD, PhD.

“We’ll also see some important updates on AEGEAN—looking at ctDNA [circulating tumor DNA] dynamics—from Martin Reck, and we’ll get an update on Checkmate 77T, a study looking at perioperative nivolumab,” Dr. Liu said.

In addition, Dr. Liu explained that a major update will be given in the neoadjuvant space, with Jamie E. Chaft, MD, of the Memorial Sloan Kettering Cancer Center presenting data from NeoADAURA, which will address key questions about the impact of osimertinib in this setting for patients with EGFR-mutated NSCLC.

He also highlighted the upcoming presentation on the efficacy of zipalertinib for patients with NSCLC who have EGFR exon 20 insertion mutations and had received prior platinum-based chemotherapy with or without amivantamab, to be presented by Helena Alexandra Yu, MD, of the Memorial Sloan Kettering Cancer Center.

Also in the EGFR-positive NSCLC space, Dr. Liu spoke about the upcoming presentation on data from the phase 3 HERTHENA-Lung02 study, to be presented by Tony S. K. Mok, MD, of the Chinese University of Hong Kong.

“We’re going to see some updates of an important study of patritumab deruxtecan in EGFR-mutated lung cancer after [tyrosine kinase inhibitor therapy],” Dr. Liu said. “This is an [antibody-drug conjugate] that we think may be able to replace second-line chemotherapy.”

Beyond the data in EGFR-positive NSCLC, Dr. Liu highlighted the TROPION-Lung02 study of datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy as a first-line therapy for advanced NSCLC, which will be presented by Benjamin Levy, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine.

“I’m looking forward to seeing those data to see if these drugs are going to have an impact in the front-line setting,” Dr. Liu said.

With the wealth of impactful data and rich datasets to review, there will be “a lot to talk about after ASCO 2025,” Dr. Liu concluded.